Lv11
58 积分 2025-11-04 加入
Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up
1天前
待确认
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
2天前
已完结
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
2天前
已完结
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis
2天前
已完结
Influence of CAR-T Product Selection on Survival and Acute Toxicities in Multiple Myeloma: A Real-World Comparative Study
6天前
已完结
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
8天前
已完结
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
2个月前
已完结
盐酸氨溴索治疗慢性阻塞性肺疾病合并肺部感染的临床效果
3个月前
已完结
金振口服液联合氨溴索治疗小儿支气管肺炎的效果分析
3个月前
已完结
Clinical experience with Ro 5-3350 (bromazepam)
4个月前
已完结
皖公网安备34019202002308
